Mitul Mehta, MD
Retina Specialist · Irvine, CANPI 1730341181
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Novartis at 26.7% of the total. Reporting peaked in 2022 at $51,300 and has fallen 86.8% since, to $6,756 in 2025. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $652.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$51K
- Apellis Pharmaceuticals, Inc.$41K
- AbbVie$38K
- Alimera Sciences, Inc.$22K
- Dutch Ophthalmic, USA$14K
- Astellas Pharma US Inc$8K
- plus $17K from 23 others
Across 5 payments — averaging $4354.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$22K
- ANI Pharmaceuticals, Inc.$158
What the payments were for
- Consulting fees$61,99432%
- Speaking & faculty fees$110,79258%
- Travel & lodging$5,1673%
- Food & beverage$13,7987%
- Education$10%
- Gifts$190%
- Entertainment$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 40 | $51,260 |
| Apellis Pharmaceuticals, Inc. | 31 | $41,080 |
| AbbVie(2 entities) | 41 | $37,912 |
| Alimera Sciences, Inc. | 31 | $22,355 |
| Dutch Ophthalmic, USA | 24 | $14,438 |
| Astellas Pharma US Inc | 24 | $8,216 |
| Eyepoint US, Inc. | 14 | $5,460 |
| Genentech USA, Inc. | 12 | $3,444 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $2,500 |
| Thrombogenics, Inc. | 3 | $1,350 |
| Regeneron Healthcare Solutions, Inc. | 27 | $1,310 |
| Bausch & Lomb Americas Inc. | 15 | $685 |
| Regeneron | 5 | $336 |
| NEW World Medical,inc. | 2 | $283 |
| Topcon Healthcare, Inc. | 3 | $212 |
| ANI Pharmaceuticals, Inc. | 2 | $153 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Carl Zeiss Meditec USA, Inc. | 2 | $112 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $90 |
| Samsara Vision | 2 | $79 |
| Kala Pharmaceuticals, Inc. | 1 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| GSK | 4 | $63 |
| Astellas Pharma Global Development | 2 | $55 |
| Astellas US LLC | 1 | $51 |
| Coherus Oncology, Inc. | 1 | $38 |
| Optos, Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$26,349
- Iluvien$21,521
- BEOVU$19,344
- OZURDEX$12,328
- EVA Ophthalmic Surgical System$8,675
- Izervay$7,514
- YUTIQ$6,979
- EVA, combined machine$5,395
- VICTUS$2,500
- STELLARIS PC$2,500
- CRYSTALENS$2,500
- TRULIGN TORIC$2,500
- Lucentis$2,465
- TISSUEBLUE$1,432
- Jetrea$1,250
- EYLEA$761
- EYLEA HD$482
- VABYSMO$293
- SUSVIMO$286
- Ahmed Glaucoma Valve$283
How this compares
$191,792 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 44 | $28,760 |
| IlevroNepafenac | 28 | $13,191 |
| Bromfenac Sodium | 52 | $7,386 |
| Cyclosporine | 14 | $3,380 |
| Alphagan PBrimonidine Tartrate | 14 | $2,735 |
| Prednisolone Acetate | 55 | $1,891 |
| Ketorolac Tromethamine | 67 | $869 |
| Timolol Maleate | 26 | $821 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 46 | $521 |
| Atropine Sulfate | 15 | $508 |
| Dorzolamide Hcl | 17 | $255 |
| Latanoprost | 19 | $148 |
| Brimonidine Tartrate | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P | $37,912 | $31,49558 claims |
| NovartisIlevro | $51,260 | $13,19128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 retina specialist providers in California.
Other retina specialist in Irvine
- Baruch KuppermannIrvine$1M
- Andrew BrowneIrvine$82K
- Nadeem VaidyaIrvine$18K
- Kapil MishraIrvine$15K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Carlos Medina MendezSacramento$548K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.